-transparent.png){kind=logo}
Psychopharmacological studies usually attempt to eliminate "nonspecific" influences on outcome by double-blind designs. In a randomized, double-blind comparison of alprazolam, imipramine, and placebo, the great majority of panic disorder patients (N = 59) and their physicians were able to rate accurately whether active drug or placebo had been given. Moreover, physicians could distinguish between the two types of active drugs. Inasmuch as correct rating was possible halfway through treatment, concerns about the internal validity of the double-blind strategy arise.
Related Publications
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
May 1995,
Sleep,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
February 1976,
Lancet (London, England),
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
February 1972,
Canadian Medical Association journal,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
April 1976,
British journal of clinical pharmacology,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
October 1974,
Canadian Medical Association journal,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
August 1994,
The Journal of the Association of Physicians of India,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
March 1969,
The American journal of psychiatry,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
January 1974,
Journal of rehabilitation,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
September 1973,
JAMA,
J Margraf, and
A Ehlers, and
W T Roth, and
D B Clark, and
J Sheikh, and
W S Agras, and
C B Taylor
December 1973,
JAMA,
